<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anaphylaxis: Confirming the diagnosis and determining the cause(s)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anaphylaxis: Confirming the diagnosis and determining the cause(s)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anaphylaxis: Confirming the diagnosis and determining the cause(s)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne K Ellis, MD, MSc, FRCPC, FAAAAI</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Kelso, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 29, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4433809"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anaphylaxis is a potentially life-threatening emergency that requires immediate diagnosis and treatment. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>Patients who have experienced anaphylaxis (or suspected anaphylaxis) require evaluation to confirm the diagnosis and determine the cause(s) and possible contributing factors, such as other medical conditions (comorbidities) and concurrent medications.</p><p class="headingAnchor" id="H4433816"><span class="h1">REFERRAL TO AN ALLERGY/IMMUNOLOGY SPECIALIST</span><span class="headingEndMark"> — </span>Referral to a board-certified allergy specialist is indicated in all cases of certain or suspected anaphylaxis [<a href="#rid1">1-5</a>]. A thorough evaluation is required to accomplish the following objectives:</p><p class="bulletIndent1"><span class="glyph">●</span>Confirm the diagnosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirm or determine the cause</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assess cofactors that might have contributed to the episode, such as exercise, alcohol, or nonsteroidal anti-inflammatory drug (NSAID) ingestion</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determine if there were other factors that contributed to the severity of anaphylaxis (eg, comorbidities, concurrent medications), which could be modified to help reduce the patient's risk of a subsequent severe anaphylactic episode</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determine if the cause of the patient's anaphylaxis is amenable to immunotherapy in the case of stinging insect allergy, in order to reduce the long-term risk of anaphylaxis recurrences</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Educate the patient/family/caregiver about avoidance measures and recognition and management of recurrent episodes (see  <a class="medical medical_review" href="/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis"</a>)</p><p></p><p>In a retrospective review of 573 adults and children evaluated in the emergency department for anaphylaxis, only 38 percent received follow-up evaluation by an allergy/immunology specialist [<a href="#rid6">6</a>]. Of those who did, the diagnosis of anaphylaxis or the suspected trigger for anaphylaxis was altered as a result of the evaluation in 35 percent. In addition, 2 percent of patients were diagnosed with a mast cell activation disorder, and 6 percent underwent immunotherapy or desensitization.</p><p>A prospective study of adults and children seen in an emergency care setting identified 226 cases of suspected anaphylaxis, of whom 124 were confirmed after diagnostic work-up in an allergy center [<a href="#rid7">7</a>]. The causative agents were medications (41 percent), stinging insect venom (27 percent), and food (21 percent), with no cause identified in 11 percent. Mastocytosis was diagnosed in 7.7 percent of adults. One or more cofactors was identified in 58 percent, including infection, exercise, NSAIDs, and alcohol.</p><p>In another study, review of medical records from a pediatric emergency department identified 133 cases of anaphylaxis by National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria. Only 70 children (53 percent) had been given the diagnosis of anaphylaxis in the emergency department, with the remainder described as urticaria, allergic reaction, or angioedema [<a href="#rid8">8</a>]. Forty-four (33 percent) had been discharged from the emergency department without information about the probable cause and thus no instructions on how to avoid future episodes. Allergy evaluations were subsequently performed in 89 percent, and a cause was identified in 92 percent of those evaluated. Food was the culprit in 90 percent of reactions, although 26 percent of children were confirmed to be allergic to a food other than that suspected in the emergency department.</p><p class="headingAnchor" id="H4433823"><span class="h1">CONFIRMING THE DIAGNOSIS OF ANAPHYLAXIS</span><span class="headingEndMark"> — </span>The initial task in evaluating a patient with a history of a recent episode of anaphylaxis is to ensure that the diagnosis is correct. Anaphylaxis presents with the sudden onset of signs and symptoms, usually in more than one body system, within minutes to a few hours of exposure to a trigger or sometimes spontaneously [<a href="#rid1">1-5</a>]. It potentially involves more than 40 signs and symptoms  (<a class="graphic graphic_table graphicRef72225" href="/d/graphic/72225.html" rel="external">table 1</a>) [<a href="#rid9">9</a>]. The diagnosis and immediate management of anaphylaxis is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>The steps involved in confirming the diagnosis of anaphylaxis, after the acute event, are depicted in the algorithm  (<a class="graphic graphic_algorithm graphicRef76947" href="/d/graphic/76947.html" rel="external">algorithm 1</a>). Each of these steps is discussed in detail in the sections that follow.</p><p>The diagnosis of anaphylaxis is confirmed if the nature and timing of the event are consistent with the known signs and symptoms and chronology of anaphylaxis [<a href="#rid1">1-5</a>]. However, the diagnosis of anaphylaxis is not always easy to make, particularly if it is the initial episode. Because anaphylaxis is a potentially fatal medical emergency [<a href="#rid10">10,11</a>], even if the diagnosis is uncertain, the patient should be equipped to self-treat a potential recurrence, and if another episode occurs, the clinician should plan to re-evaluate the patient and ascertain if exposures common to both the episodes can be detected. (See  <a class="medical medical_review" href="/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis"</a>.)</p><p class="headingAnchor" id="H4433830"><span class="h2">History of exposures and activities</span><span class="headingEndMark"> — </span>The clinical history is supremely important in making the diagnosis of anaphylaxis, determining the cause(s), and assessing the patient for contributing factors that might increase the risk of severe or fatal anaphylaxis.</p><p>Each past episode of anaphylaxis should be carefully reviewed, starting with the 24-hour period before the onset of symptoms and paying particular attention to the one to two hours immediately preceding symptom onset. Important information can be obtained from family members, caregivers, friends, or other witnesses, emergency medical personnel, and emergency department and hospital records.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exposures</strong> – Anything that was ingested, injected, or otherwise taken into the body during this period should be noted. Foods are the most common trigger of immunoglobulin E (IgE)-mediated anaphylaxis in children, teenagers, and young adults, while insect stings and medications are more common triggers in middle-aged or older adults. The table provides a comprehensive list of potential anaphylaxis causes, categorized by the pathophysiologic mechanism involved  (<a class="graphic graphic_table graphicRef70667" href="/d/graphic/70667.html" rel="external">table 2</a>) [<a href="#rid4">4,5,10-27</a>]. The mechanisms of anaphylaxis are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/386.html" rel="external">"Pathophysiology of anaphylaxis"</a> and  <a class="medical medical_review" href="/d/html/2397.html" rel="external">"History and physical examination in the patient with possible food allergy"</a> and  <a class="medical medical_review" href="/d/html/2398.html" rel="external">"Clinical manifestations of food allergy: An overview"</a> and  <a class="medical medical_review" href="/d/html/2079.html" rel="external">"An approach to the patient with drug allergy"</a> and  <a class="medical medical_review" href="/d/html/4091.html" rel="external">"Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronology</strong> – The chronology of events (time elapsed between exposure to trigger and onset of first symptom[s]) should be consistent with the diagnosis of anaphylaxis. IgE-mediated anaphylaxis usually develops within minutes to one hour or so of exposure. However, there are rare exceptions to this, such as IgE-mediated reactions to the carbohydrate galactose alpha-1,3-galactose (alpha-gal) in red meat, which develop four to six hours after ingestion [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/2393.html" rel="external">"Allergy to meats", section on 'IgE-mediated reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline state of health and activities</strong> – Patients should be asked about their general health and their activities in the 24 hours preceding symptom onset [<a href="#rid10">10,11,29</a>]. Relevant history includes any illness and any medications taken as treatment, fever, or menstrual state. These factors may render patients more susceptible to anaphylaxis and/or exacerbate anaphylaxis symptoms.</p><p></p><p class="bulletIndent1">Physical activity should be reviewed [<a href="#rid1">1,4,5,16</a>]. Exercise can be the only trigger for an anaphylactic episode (exercise-induced anaphylaxis) or it may only induce symptoms when preceded by ingestion of food or medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs). Sometimes specific foods, such as shellfish, wheat, or celery, combined with exercise, will trigger symptoms (food-dependent, exercise-induced anaphylaxis), while in other cases, any food ingestion followed shortly by exercise can trigger an episode. (See  <a class="medical medical_review" href="/d/html/384.html" rel="external">"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Uncommonly, allergen exposure can occur through kissing or intercourse [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/2406.html" rel="external">"Management of food allergy: Avoidance", section on 'Interpersonal contact'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environmental conditions</strong> – Exposure to unusual environmental conditions should be reviewed because anaphylaxis symptoms can be triggered or exacerbated by heat or cold [<a href="#rid5">5,16</a>]. (See  <a class="medical medical_review" href="/d/html/8109.html" rel="external">"Physical (inducible) forms of urticaria"</a> and  <a class="medical medical_review" href="/d/html/8102.html" rel="external">"Cold urticaria"</a>.)</p><p></p><p class="headingAnchor" id="H2769022444"><span class="h3">Nocturnal anaphylaxis</span><span class="headingEndMark"> — </span>A small number of allergens can cause primarily nocturnal anaphylaxis, awakening patients from sleep:</p><p class="bulletIndent1"><span class="glyph">●</span>Alpha-gal in red meat, which most commonly presents with anaphylaxis beginning four to six hours after a meal containing beef, pork, or lamb. (See  <a class="medical medical_review" href="/d/html/2393.html" rel="external">"Allergy to meats", section on 'IgE-mediated reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergens in the saliva of kissing bugs that typically bite during the night. (See  <a class="medical medical_review" href="/d/html/4087.html" rel="external">"Reactions to bites from kissing bugs (primarily genus <i>Triatoma</i>)", section on 'Allergic reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergens in the bites of pigeon ticks (<em>Argas reflexus</em>), which feed by night and are mostly encountered in middle and southern European cities where pigeons are prevalent [<a href="#rid30">30-33</a>].</p><p></p><p class="headingAnchor" id="H1824547"><span class="h3">Comorbidities</span><span class="headingEndMark"> — </span>Certain chronic health conditions increase the risk of severe or fatal anaphylaxis [<a href="#rid9">9,34-40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Asthma, especially if symptoms are not optimally controlled, is an important risk factor for severe or fatal anaphylaxis [<a href="#rid11">11,34,35</a>]. (See  <a class="medical medical_review" href="/d/html/2401.html" rel="external">"Food-induced anaphylaxis", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/d/html/390.html" rel="external">"Fatal anaphylaxis", section on 'Asthma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other pulmonary and cardiac diseases, including chronic obstructive pulmonary disease (COPD) and coronary artery disease, increase the risk of severe anaphylactic reactions and fatality [<a href="#rid1">1,2,4,36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mastocytosis or other mast cell disorders are associated with increased risk of life-threatening or fatal anaphylaxis [<a href="#rid38">38-40</a>]. These disorders should be considered particularly in patients with severe anaphylaxis. (See  <a class="medical medical_review" href="/d/html/15715.html" rel="external">"Mast cell disorders: An overview"</a>.)</p><p></p><p class="headingAnchor" id="H4433837"><span class="h3">Concurrent medications and other substances</span><span class="headingEndMark"> — </span>All medications and substances ingested or used (prescription, over-the-counter, and recreational) in the 24 hours immediately preceding the anaphylaxis episode should be reviewed. Some medications may affect the patient's likelihood of developing anaphylaxis, the ability to respond with compensatory physiologic changes, or the response to treatment  (<a class="graphic graphic_table graphicRef65161" href="/d/graphic/65161.html" rel="external">table 3</a>) [<a href="#rid41">41-44</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol, NSAIDs, and opiates can exacerbate anaphylaxis symptoms by causing nonimmunologic mast cell activation [<a href="#rid1">1,10,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta-adrenergic blockers administered orally or topically (eg, eye drops) may potentially make anaphylaxis more difficult to treat by causing unopposed alpha-adrenergic effects and hypertension and reduced bronchodilator response to the beta-adrenergic effects of endogenous or exogenous <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment", section on 'Glucagon for patients taking beta blockers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiotensin-converting enzyme (ACE) inhibitors potentially interfere with endogenous compensatory mechanisms, resulting in more severe or prolonged symptoms [<a href="#rid43">43</a>]. Angiotensin II receptor blockers are less likely to have this effect. However, this is not optimally documented [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combination of ACE inhibitors and beta-blockers may synergistically increase the risk of severe anaphylaxis [<a href="#rid45">45</a>].</p><p></p><p>If a patient is taking a medication that might have contributed to anaphylaxis or interfered with its treatment, discontinuing use of that medication should be considered. The overall benefits and risks of that drug need to be assessed and discussed not only with the patient but also with other health care professionals involved in his/her care. Where appropriate, substitution should be considered [<a href="#rid41">41-44</a>]. This is reviewed separately. (See  <a class="medical medical_review" href="/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis"</a>.)</p><p class="headingAnchor" id="H4433844"><span class="h2">Review of treatment</span><span class="headingEndMark"> — </span>Emergency medical services records and emergency department records should be reviewed, specifically with regard to symptoms and signs of anaphylaxis, as well as all medications that were given and the times at which they were administered. <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> is highly effective when injected intramuscularly promptly after symptom onset. Therefore, the timing of epinephrine injection(s), the dose in relationship to the patient's weight, and the route and site of injection are important in the interpretation of the clinical response [<a href="#rid1">1-5</a>]. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment", section on 'Treatment errors'</a>.)</p><p>A review of the patient's, family's, or caregiver's response to the anaphylactic episode may help to identify behaviors that contributed to the severity of the episode and could be modified to reduce future risk.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients experiencing food-induced anaphylaxis in a restaurant or other public setting sometimes go to the restroom and separate themselves from those who can assist them, potentially leading to delay in injecting <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, contacting emergency medical services, and even fatality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who collapse during anaphylaxis are sometimes propped up in the sitting position by well-meaning family or friends, resulting in inadequate cardiac preload, pulseless electrical activity, and sudden death [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/390.html" rel="external">"Fatal anaphylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with exercise-induced anaphylaxis sometimes try to run for help at the onset of symptoms, although continued exertion after symptom onset is likely to exacerbate the episode [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/384.html" rel="external">"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/385.html" rel="external">"Exercise-induced anaphylaxis: Management and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H4433851"><span class="h2">Laboratory test results obtained at the time of anaphylaxis</span><span class="headingEndMark"> — </span>The results of serum tryptase measurements obtained at the time of the anaphylactic episode should ideally be obtained and reviewed [<a href="#rid1">1,47-49</a>]. Tryptase levels are mentioned briefly here as an example and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis"</a>.)</p><p>The diagnosis of anaphylaxis is based on a history of sudden onset and rapid evolution of characteristic symptoms and signs, usually in more than one organ system (see  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>). An elevated serum tryptase level supports the diagnosis, but a normal level cannot refute the diagnosis.</p><p class="bulletIndent1"><span class="glyph">●</span>Serum tryptase level results are not available on an emergency basis, because the assay takes several hours to perform but are nonetheless important to obtain to assist in retrospective confirmation of anaphylaxis and to rule out mast cell disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The blood sample for serum tryptase measurement is optimally obtained 1 to 3 hours after the onset of anaphylaxis symptoms. A second measurement of baseline serum tryptase at least 24 hours after resolution of the clinical signs and symptoms of anaphylaxis should be performed for comparison.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the event-related tryptase level is greater than 11.4 ng/mL or elevated by at least 20 percent above baseline plus 2 ng/mL and tryptase returns to normal after the event, then the diagnosis of anaphylaxis is confirmed. If the level is greater than 11.4 ng/mL in both acute and baseline sera, the diagnosis of mastocytosis or other mast cell disorders should be considered [<a href="#rid1">1,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum tryptase is most often elevated in anaphylaxis triggered by insect stings or medications and in patients with anaphylaxis from any cause who are hypotensive or in shock. Tryptase levels may not be elevated in food-induced anaphylaxis or in patients with anaphylaxis who are normotensive. Tryptase levels that are within normal limits cannot be used to rule out the clinical diagnosis of anaphylaxis. (See  <a class="medical medical_review" href="/d/html/2401.html" rel="external">"Food-induced anaphylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum tryptase levels are not specific for anaphylaxis. They may be elevated in patients with acute myeloid leukemia or renal failure and in some healthy individuals (eg, those with hereditary alpha-tryptasemia). The differential diagnosis of elevations in serum tryptase is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Elevations of tryptase in nonanaphylactic patients'</a>.)</p><p></p><p class="headingAnchor" id="H4433858"><span class="h1">TESTING FOR ALLERGEN CAUSE(S)</span><span class="headingEndMark"> — </span>Every effort should be made to identify the cause of a patient's anaphylaxis, as this greatly increases his or her chances of avoiding this exposure and preventing recurrence of anaphylaxis  (<a class="graphic graphic_algorithm graphicRef63559" href="/d/graphic/63559.html" rel="external">algorithm 2</a>). In addition, attributing anaphylaxis incorrectly to the "wrong" allergen potentially puts the patient at greater risk from exposure to the true culprit allergen.</p><p>The list of reported causes of anaphylaxis, including foods, medications, and insect stings or bites continues to lengthen  (<a class="graphic graphic_table graphicRef70667" href="/d/graphic/70667.html" rel="external">table 2</a>) [<a href="#rid4">4,18,19</a>]. The clinical history, gathered as described above, is the best means of identifying a suspect cause and possible cofactors. (See <a class="local">'History of exposures and activities'</a> above.)</p><p>Attempts should be made to verify the cause even when the clinical history strongly implicates a single, apparently isolated exposure, such as an insect sting [<a href="#rid5">5,20,21</a>]. In this example, the results of venom-specific skin tests and/or immunoglobulin E (IgE) levels are needed to identify the allergen and also determine if there are other related venoms to which the patient is also sensitized. Such tests are important because a course of subcutaneous injections with the relevant stinging insect venom(s) (honey bee, yellow jacket, wasp, or hornet) or whole body extract (fire ant) will significantly reduce the patient's risk of recurrence of anaphylaxis to a sting.</p><p>In many cases of anaphylaxis, the trigger is not immediately apparent. Sometimes patients draw their own conclusions about what the likely cause was and report this as an established allergy to future clinicians. It is important for health care professionals to ask patients with past anaphylaxis if the cause was verified by an allergist or proven in some other way, since the patient may be avoiding the wrong allergens and may be at risk for future recurrences.</p><p class="headingAnchor" id="H4433865"><span class="h2">Sensitization to allergens</span><span class="headingEndMark"> — </span>In patients with anaphylaxis attributed to an IgE-mediated allergy, positive allergen skin tests and/or elevated allergen-specific IgE levels in serum confirm sensitization to the allergen(s) tested. (See  <a class="medical medical_review" href="/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease"</a> and  <a class="medical medical_review" href="/d/html/5540.html" rel="external">"Overview of in vitro allergy tests"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Skin testing with allergen extracts is the traditional method for demonstrating sensitization. Extracts are commercially available for most foods, venoms, and penicillin but not for other antibiotics [<a href="#rid1">1,5,20,21</a>]. In patients with a strong history of food-induced anaphylaxis, if tests with commercial extracts are negative or not available, the suspect food itself can be used for skin prick testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In vitro testing provides quantitative results expressed in standardized units [<a href="#rid18">18,19</a>]. Specific IgE levels measured using different assay systems are not exactly interchangeable [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/2396.html" rel="external">"Diagnostic evaluation of IgE-mediated food allergy"</a> and  <a class="medical medical_review" href="/d/html/5540.html" rel="external">"Overview of in vitro allergy tests"</a>.)</p><p></p><p class="bulletIndent1">Various enzyme-linked immunosorbent assays (ELISAs) for quantification of allergen-specific IgE levels in serum have replaced radioallergosorbent tests (RASTs) in clinical laboratories, although the term "RAST" remains in use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If anaphylaxis to a medication, biologic agent, or vaccine is suggested by the history, skin tests and/or in vitro tests should be performed with the implicated agent and with the relevant excipients that it contains [<a href="#rid22">22-27</a>]. (See  <a class="medical medical_review" href="/d/html/2079.html" rel="external">"An approach to the patient with drug allergy", section on 'Objective testing'</a> and  <a class="medical medical_review" href="/d/html/2074.html" rel="external">"Allergic reactions to vaccines"</a>.)</p><p></p><p class="bulletIndent1">Patients with a recent history of a sudden onset multisystem clinical reaction to a specific food, drug, or venom in combination with a positive skin test and/or an elevated specific IgE level to that substance do <strong>not</strong> require a challenge for definitive diagnosis. In such patients, challenges are likely to trigger anaphylaxis [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/2396.html" rel="external">"Diagnostic evaluation of IgE-mediated food allergy"</a> and  <a class="medical medical_review" href="/d/html/5540.html" rel="external">"Overview of in vitro allergy tests"</a>.)</p><p></p><p>The results of skin tests and in vitro tests for allergen-specific IgE must always be interpreted in the context of the patient's clinical history for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>A positive test result documents sensitization (presence of IgE antibody) to the allergen. However, it does not necessarily prove that the allergen is the causative trigger for symptoms [<a href="#rid49">49</a>]. For reasons that are poorly understood, it is possible to have clinically irrelevant positive tests. For example, more than 25 percent of all adults in the general population have one or more positive skin test responses to stinging insect venoms, yet most of these individuals do not experience anaphylaxis after a sting. However, given a clinical history of a sting shortly before the onset of symptoms of anaphylaxis, any venom sensitization is considered relevant (ie, establishes IgE-mediated venom allergy as the cause of the event).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>False-negative tests are also possible. In patients with a history of anaphylaxis but negative tests to the implicated allergen, incremental challenge/provocation tests may be required to exclude or confirm a specific allergen as the cause [<a href="#rid18">18,19,22,23</a>]. These procedures are time-consuming and associated with some risk to the patient. They should only be conducted in appropriately staffed and equipped facilities by health care professionals with training and experience in patient selection, patient assessment on the day of challenge, and in the recognition and treatment of anaphylaxis. (See  <a class="medical medical_review" href="/d/html/2399.html" rel="external">"Oral food challenges for diagnosis and management of food allergies"</a> and  <a class="medical medical_review" href="/d/html/2079.html" rel="external">"An approach to the patient with drug allergy", section on 'Graded challenge and drug provocation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There may also be a "refractory period" for skin tests and possibly serum-specific IgE tests after an anaphylactic episode, ranging from one to four weeks [<a href="#rid51">51,52</a>]. If an individual has experienced anaphylaxis triggered by an allergen suggested by the history, yet has negative skin test responses and undetectable specific IgE levels in serum shortly after the episode, the tests should be repeated four to six weeks later [<a href="#rid4">4,5</a>]. The interpretation of skin testing and in vitro testing for allergic disease is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease"</a> and  <a class="medical medical_review" href="/d/html/5540.html" rel="external">"Overview of in vitro allergy tests"</a>.)</p><p></p><p class="headingAnchor" id="H4433872"><span class="h2">Testing for related allergies</span><span class="headingEndMark"> — </span>If a specific trigger can be identified, it is sometimes necessary to determine if the patient is sensitive to similar substances. This information is used to help the patient avoid all relevant substances and to identify safe alternatives. Examples include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A patient with anaphylaxis in response to a yellow jacket sting should undergo testing with venoms from all members of the flying Hymenoptera species and be offered immunotherapy that included all the venoms to which he/she is sensitized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with anaphylaxis to certain tree nuts is likely to react to certain cross-reacting tree nuts but not to others.</p><p></p><p class="headingAnchor" id="H4433879"><span class="h1">THE PATIENT WITH AN IDENTIFIABLE CAUSE</span><span class="headingEndMark"> — </span>All patients with anaphylaxis must be taught how to recognize and manage anaphylaxis if and when it recurs, including correct use of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors. This is true even when a trigger has been identified because accidental ingestions of foods are common, and insect stings cannot be avoided. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis"</a> and  <a class="medical medical_review" href="/d/html/388.html" rel="external">"Prescribing epinephrine for anaphylaxis self-treatment"</a> and  <a class="medical medical_patient" href="/d/html/365.html" rel="external">"Patient education: Using an epinephrine autoinjector (Beyond the Basics)"</a>.)</p><p>Patients with an identifiable cause must also be given instructions about avoidance. The educational process, as well as tools and resources to assist patients and clinicians, are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis"</a> and  <a class="medical medical_review" href="/d/html/2406.html" rel="external">"Management of food allergy: Avoidance"</a> and  <a class="medical medical_review" href="/d/html/5554.html" rel="external">"Latex allergy: Management", section on 'Individual avoidance'</a>.)</p><p>Anaphylaxis to stinging insects can be prevented by immunotherapy with the relevant insect venom(s), and anaphylaxis to certain medications can be prevented by desensitization. A complete list of the available desensitization therapies is found elsewhere. (See  <a class="medical medical_review" href="/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis", section on 'Interventions to reduce sensitivity'</a>.)</p><p class="headingAnchor" id="H4433886"><span class="h1">THE PATIENT WITH NO IDENTIFIABLE CAUSE</span><span class="headingEndMark"> — </span>In some cases, no trigger can be identified by history or tests to explain a patient's anaphylactic episode. In this situation, it is important to reconsider the differential diagnosis of anaphylaxis and to consider the possibility of a hidden or novel trigger. In addition, hereditary alpha tryptasemia, a heritable disorder that exists in up to 5 percent of the general population, as well as rare mast cell disorders (including systemic mastocytosis and monoclonal mast cell activation syndrome), should be excluded, especially in patients with repeated episodes of anaphylaxis or anaphylaxis-like symptoms [<a href="#rid38">38-40</a>]. (See  <a class="medical medical_review" href="/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Hereditary alpha tryptasemia'</a> and  <a class="medical medical_review" href="/d/html/15715.html" rel="external">"Mast cell disorders: An overview"</a>.)</p><p>The diagnosis of idiopathic anaphylaxis is assigned when no trigger can be identified and mast cell disorders have been excluded [<a href="#rid53">53</a>]. In two studies of patients treated for anaphylaxis in the emergency department and subsequently evaluated by allergists, a cause could not be identified in approximately 10 percent [<a href="#rid7">7,8</a>]. Consideration is then given to daily prophylactic use of H1 antihistamines or for more severe or frequent episodes, prophylaxis with glucocorticoids and potentially other medications. (See  <a class="medical medical_review" href="/d/html/387.html" rel="external">"Idiopathic anaphylaxis"</a>.)</p><p>All patients with anaphylaxis, whether or not a trigger is identified, must be taught how to recognize and manage anaphylaxis if and when it recurs, including prompt use of <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors [<a href="#rid2">2,4</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis"</a> and  <a class="medical medical_review" href="/d/html/388.html" rel="external">"Prescribing epinephrine for anaphylaxis self-treatment"</a> and  <a class="medical medical_patient" href="/d/html/365.html" rel="external">"Patient education: Using an epinephrine autoinjector (Beyond the Basics)"</a>.)</p><p class="headingAnchor" id="H1547647929"><span class="h1">DIFFERENTIAL DIAGNOSIS OF ANAPHYLAXIS</span><span class="headingEndMark"> — </span>The differential diagnosis of anaphylaxis is broad. It includes common entities, such as acute asthma, acute generalized hives, anxiety/panic attack, syncope/faint, and choking on/aspiration of a foreign body, as well as less common entities, such as vocal cord dysfunction, flushing syndromes, and postprandial syndromes [<a href="#rid1">1,4,5</a>]. The differential diagnosis also varies with age and physiologic state [<a href="#rid12">12-15</a>]. Relevant topics include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/395.html" rel="external">"Differential diagnosis of anaphylaxis in adults and children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5750.html" rel="external">"Anaphylaxis in infants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2782.html" rel="external">"Approach to flushing in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/393.html" rel="external">"Anaphylaxis during pregnancy and delivery"</a>.)</p><p></p><p class="headingAnchor" id="H2249759880"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105526.html" rel="external">"Society guideline links: Anaphylaxis"</a>.)</p><p class="headingAnchor" id="H4433893"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have experienced anaphylaxis should be referred to an allergy/immunology specialist to confirm the diagnosis, confirm or determine the causes(s), and determine relevant patient risk factors for severe or fatal anaphylaxis (eg, comorbidities or concurrent medications that could be modified to reduce the patient's risk of recurrences in the future). In addition, some forms of anaphylaxis are amenable to prevention through immunomodulation. (See <a class="local">'Referral to an allergy/immunology specialist'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation involves retaking a detailed medical history of each episode of symptoms and reviewing relevant medical records and laboratory test results. (See <a class="local">'Confirming the diagnosis of anaphylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Every effort should be made to confirm the specific cause for anaphylaxis suggested by the patient's history in order to provide appropriate recommendations for avoidance, begin immunotherapy or desensitization (if relevant), and prevent future anaphylaxis episodes. (See <a class="local">'Testing for allergen cause(s)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If no cause is identified, the differential diagnosis of anaphylaxis should be reconsidered, and the possibility of a hidden or novel trigger should be explored. All patients with episodes of anaphylaxis and no identifiable causes should be assessed for a mast cell disorder. (See <a class="local">'The patient with no identifiable cause'</a> above and  <a class="medical medical_review" href="/d/html/387.html" rel="external">"Idiopathic anaphylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with anaphylaxis require regular education about how to recognize and manage recurrent anaphylaxis and about avoidance of confirmed allergen triggers. (See  <a class="medical medical_review" href="/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis"</a>.)</p><p></p><p class="headingAnchor" id="H3202958662"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge F Estelle R Simons, MD, FRCPC, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Simons FE. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161.</a></li><li><a class="nounderline abstract_t">Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.</a></li><li><a class="nounderline abstract_t">Sampson HA, Muñoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584.</a></li><li><a class="nounderline abstract_t">Simons FE, Ardusso LR, Bilò MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011; 127:587.</a></li><li><a class="nounderline abstract_t">Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145:1082.</a></li><li><a class="nounderline abstract_t">Campbell RL, Park MA, Kueber MA Jr, et al. Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis. J Allergy Clin Immunol Pract 2015; 3:88.</a></li><li><a class="nounderline abstract_t">Oropeza AR, Bindslev-Jensen C, Broesby-Olsen S, et al. Patterns of anaphylaxis after diagnostic workup: A follow-up study of 226 patients with suspected anaphylaxis. Allergy 2017; 72:1944.</a></li><li><a class="nounderline abstract_t">Alvarez-Perea A, Ameiro B, Morales C, et al. Anaphylaxis in the Pediatric Emergency Department: Analysis of 133 Cases After an Allergy Workup. J Allergy Clin Immunol Pract 2017; 5:1256.</a></li><li><a class="nounderline abstract_t">Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367.</a></li><li><a class="nounderline abstract_t">Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.</a></li><li><a class="nounderline abstract_t">Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.</a></li><li><a class="nounderline abstract_t">Alves B, Sheikh A. Age specific aetiology of anaphylaxis. Arch Dis Child 2001; 85:348.</a></li><li><a class="nounderline abstract_t">Simons FE. Anaphylaxis in infants: can recognition and management be improved? J Allergy Clin Immunol 2007; 120:537.</a></li><li><a class="nounderline abstract_t">Simons FE, Schatz M. Anaphylaxis during pregnancy. J Allergy Clin Immunol 2012; 130:597.</a></li><li><a class="nounderline abstract_t">Campbell RL, Hagan JB, Li JT, et al. Anaphylaxis in emergency department patients 50 or 65 years or older. Ann Allergy Asthma Immunol 2011; 106:401.</a></li><li><a class="nounderline abstract_t">Robson-Ansley P, Toit GD. Pathophysiology, diagnosis and management of exercise-induced anaphylaxis. Curr Opin Allergy Clin Immunol 2010; 10:312.</a></li><li><a class="nounderline abstract_t">Matsuo H, Kaneko S, Tsujino Y, et al. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) on serum allergen levels after wheat ingestion. J Dermatol Sci 2009; 53:241.</a></li><li><a class="nounderline abstract_t">Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol 2010; 126:1105.</a></li><li><a class="nounderline abstract_t">Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol 2014; 133:291.</a></li><li><a class="nounderline abstract_t">Bilò MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009; 39:1467.</a></li><li><a class="nounderline abstract_t">Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol 2017; 118:28.</a></li><li><a class="nounderline abstract_t">Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol 2010; 125:S126.</a></li><li><a class="nounderline abstract_t">Mirakian R, Ewan PW, Durham SR, et al. BSACI guidelines for the management of drug allergy. Clin Exp Allergy 2009; 39:43.</a></li><li><a class="nounderline abstract_t">Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am 2009; 29:585.</a></li><li><a class="nounderline abstract_t">Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008; 100:S1.</a></li><li><a class="nounderline abstract_t">Rezvani M, Bernstein DI. Anaphylactic reactions during immunotherapy. Immunol Allergy Clin North Am 2007; 27:295.</a></li><li><a class="nounderline abstract_t">Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012; 130:25.</a></li><li><a class="nounderline abstract_t">Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2009; 123:426.</a></li><li><a class="nounderline abstract_t">Summers CW, Pumphrey RS, Woods CN, et al. Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center. J Allergy Clin Immunol 2008; 121:632.</a></li><li><a class="nounderline abstract_t">Rolla G, Heffler E, Boita M, et al. Pigeon tick bite: A neglected cause of idiopathic nocturnal anaphylaxis. Allergy 2018; 73:958.</a></li><li><a class="nounderline abstract_t">Spiewak R, Lundberg M, Johansson G, Buczek A. Allergy to pigeon tick (Argas reflexus) in Upper Silesia, Poland. Ann Agric Environ Med 2006; 13:107.</a></li><li><a class="nounderline abstract_t">Weckesser S, Hilger C, Lentz D, Jakob T. Anaphylactic reactions to bites of the pigeon tick Argas reflexus. Eur J Dermatol 2010; 20:244.</a></li><li><a class="nounderline abstract_t">Quercia O, Emiliani F, Foschi FG, Stefanini GF. Anaphylactic shock to Argas reflexus bite. Eur Ann Allergy Clin Immunol 2005; 37:66.</a></li><li><a class="nounderline abstract_t">González-Pérez A, Aponte Z, Vidaurre CF, Rodríguez LA. Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review. J Allergy Clin Immunol 2010; 125:1098.</a></li><li><a class="nounderline abstract_t">Iribarren C, Tolstykh IV, Miller MK, Eisner MD. Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system. Ann Allergy Asthma Immunol 2010; 104:371.</a></li><li><a class="nounderline abstract_t">Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 Suppl 1:7.</a></li><li><a class="nounderline abstract_t">Mueller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7:337.</a></li><li><a class="nounderline abstract_t">Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med 2015; 373:163.</a></li><li><a class="nounderline abstract_t">Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017; 140:349.</a></li><li><a class="nounderline abstract_t">Metcalfe DD, Schwartz LB. Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol 2009; 123:687.</a></li><li><a class="nounderline abstract_t">Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol 2010; 10:354.</a></li><li><a class="nounderline abstract_t">TenBrook JA Jr, Wolf MP, Hoffman SN, et al. Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. J Allergy Clin Immunol 2004; 113:977.</a></li><li><a class="nounderline abstract_t">Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.</a></li><li><a class="nounderline abstract_t">Caviglia AG, Passalacqua G, Senna G. Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? J Allergy Clin Immunol 2010; 125:1171; author reply 1171.</a></li><li><a class="nounderline abstract_t">Nassiri M, Babina M, Dölle S, et al. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol 2015; 135:491.</a></li><li><a class="nounderline abstract_t">Pumphrey RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol 2003; 112:451.</a></li><li><a class="nounderline abstract_t">Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26:451.</a></li><li><a class="nounderline abstract_t">Komarow HD, Hu Z, Brittain E, et al. Serum tryptase levels in atopic and nonatopic children. J Allergy Clin Immunol 2009; 124:845.</a></li><li><a class="nounderline abstract_t">Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120:S2.</a></li><li><a class="nounderline abstract_t">Müller UR. Elevated baseline serum tryptase, mastocytosis and anaphylaxis. Clin Exp Allergy 2009; 39:620.</a></li><li><a class="nounderline abstract_t">Goldberg A, Confino-Cohen R. Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. J Allergy Clin Immunol 1997; 100:182.</a></li><li><a class="nounderline abstract_t">Soetens F, Rose M, Fisher M. Timing of skin testing after a suspected anaphylactic reaction during anaesthesia. Acta Anaesthesiol Scand 2012; 56:1042.</a></li><li><a class="nounderline abstract_t">Greenberger PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:273.</a></li></ol></div><div id="topicVersionRevision">Topic 391 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176258" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461139" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753908" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Symposium on the definition and management of anaphylaxis: summary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21377030" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : World Allergy Organization anaphylaxis guidelines: summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001253" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577624" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28543193" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Patterns of anaphylaxis after diagnostic workup: A follow-up study of 226 patients with suspected anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28389303" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Anaphylaxis in the Pediatric Emergency Department: Analysis of 133 Cases After an Allergy Workup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461138" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anaphylaxis, killer allergy: long-term management in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349682" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Further fatal allergic reactions to food in the United Kingdom, 1999-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17306354" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Further fatalities caused by anaphylactic reactions to food, 2001-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572233" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Age specific aetiology of anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765754" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Anaphylaxis in infants: can recognition and management be improved?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22871389" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anaphylaxis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21530872" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anaphylaxis in emergency department patients 50 or 65 years or older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20543674" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pathophysiology, diagnosis and management of exercise-induced anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18947983" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of non-steroidal anti-inflammatory drugs (NSAIDs) on serum allergen levels after wheat ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134568" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388012" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622088" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The natural history and epidemiology of insect venom allergy: clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28007086" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Stinging insect hypersensitivity: A practice parameter update 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176256" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Drug allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19128352" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : BSACI guidelines for the management of drug allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19563999" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Rapid desensitization for hypersensitivity reactions to medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18431959" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Allergy diagnostic testing: an updated practice parameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493504" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anaphylactic reactions during immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608573" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adverse reactions to vaccines practice parameter 2012 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19070355" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18207562" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29083476" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pigeon tick bite: A neglected cause of idiopathic nocturnal anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16841881" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Allergy to pigeon tick (Argas reflexus) in Upper Silesia, Poland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20123639" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anaphylactic reactions to bites of the pigeon tick Argas reflexus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15859366" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Anaphylactic shock to Argas reflexus bite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20392483" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20486326" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721322" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Allergy and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620826" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cardiovascular disease and anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26154789" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mast Cells, Mastocytosis, and Related Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780942" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mast cell activation syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281912" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Assessing anaphylactic risk? Consider mast cell clonality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20543673" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epinephrine and its use in anaphylaxis: current issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131583" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19895993" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347124" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25441633" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897756" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fatal posture in anaphylactic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931288" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Diagnostic value of tryptase in anaphylaxis and mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665778" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Serum tryptase levels in atopic and nonatopic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17602945" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk assessment in anaphylaxis: current and future approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400907" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Elevated baseline serum tryptase, mastocytosis and anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9275138" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Timing of venom skin tests and IgE determinations after insect sting anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22313451" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Timing of skin testing after a suspected anaphylactic reaction during anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493503" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Idiopathic anaphylaxis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
